Abrocitinib Shows Age-Linked Safety Differences
Recent analysis reveals abrocitinib’s long-term safety in atopic dermatitis, highlighting age-related risks and the importance of tailored dosing for older patients.
Related Articles
Artificial Intelligence–Enabled Wearable Devices and Nocturnal Scratching in Mild Atopic Dermatitis
This cohort study evaluates the accuracy and efficacy of an artificial intelligence–enabled wearable sensor with closed-loop haptic feedback to decrease nocturnal scratch in patients with…
Hair & Scalp Disorders: The RX Pad and Beyond Virtual Event
Hair and scalp disorders are among the most common yet challenging conditions in dermatology, often leaving providers searching for more effective, evidence-based treatment strategies. Hair…
Missed Diagnoses, Missed Opportunities: Closing the Gap in Skin Cancer for Patients of Color
Explore the urgent need for improved skin cancer awareness and care for minority populations, addressing disparities in diagnosis and treatment.
Switching Gears in Atopic Dermatitis: How Upadacitinib Helps Patients Reach Optimal Targets After Dupilumab Inadequacy
Data from the Level Up study shows that switching from dupilumab to upadacitinib enables more patients to achieve optimal targets of skin clearance and itch…
Manage Acute Flares in Atopic Dermatitis
Test your knowledge on managing acute flares in atopic dermatitis. Learn about eczema action plans, proactive care models, and key patient education strategies to improve…
Delphi Panel for the Development of Diagnostic Criteria for Metastatic Cutaneous Crohn Disease
This consensus statement establishes diagnostic criteria for metastatic cutaneous Crohn disease from a panel of experts on the disease.
AAD Partners With SOCS to Launch Inclusive Image Library
The Clinical Image Collection enhances dermatologic education by providing diverse images of skin conditions, promoting inclusivity and accurate diagnoses across all skin tones.
Perspective in Rheumatic Diseases
We know that connecting with colleagues is essential. Meet new colleagues and catch up with everyone in your professional circle. Join us for the 2024…